Evolocumab ( AMG 145 ) , a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) , significantly reduced low-density lipoprotein cholesterol ( LDL-C ) in phase 2 studies of 12 weeks ' duration .